FR22C1000I1 - Anticorps se liant a il-17a et il-17f - Google Patents
Anticorps se liant a il-17a et il-17fInfo
- Publication number
- FR22C1000I1 FR22C1000I1 FR22C1000C FR22C1000I1 FR 22C1000 I1 FR22C1000 I1 FR 22C1000I1 FR 22C1000 C FR22C1000 C FR 22C1000C FR 22C1000 I1 FR22C1000 I1 FR 22C1000I1
- Authority
- FR
- France
- Prior art keywords
- antibodies binding
- antibodies
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161432814P | 2011-01-14 | 2011-01-14 | |
EP12700433.1A EP2663577B1 (fr) | 2011-01-14 | 2012-01-11 | Nticorps se liant à il-17a et il-17f |
Publications (2)
Publication Number | Publication Date |
---|---|
FR22C1000I1 true FR22C1000I1 (fr) | 2022-02-18 |
FR22C1000I2 FR22C1000I2 (fr) | 2022-12-30 |
Family
ID=45496193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR22C1000C Active FR22C1000I2 (fr) | 2011-01-14 | 2022-01-04 | Anticorps se liant a il-17a et il-17f |
Country Status (36)
Country | Link |
---|---|
US (5) | US8580265B2 (fr) |
EP (2) | EP2663577B1 (fr) |
JP (2) | JP6028737B2 (fr) |
KR (1) | KR101950306B1 (fr) |
CN (1) | CN103384682B (fr) |
AR (2) | AR084845A1 (fr) |
AU (1) | AU2012206431B2 (fr) |
BR (1) | BR112013017951B1 (fr) |
CA (1) | CA2823812C (fr) |
CL (1) | CL2013002044A1 (fr) |
CO (1) | CO6781516A2 (fr) |
CY (1) | CY1119055T1 (fr) |
DK (1) | DK2663577T3 (fr) |
EA (1) | EA037071B1 (fr) |
ES (1) | ES2632583T3 (fr) |
FI (1) | FIC20220002I1 (fr) |
FR (1) | FR22C1000I2 (fr) |
HR (1) | HRP20171034T1 (fr) |
HU (1) | HUS2200001I1 (fr) |
IL (1) | IL227347B (fr) |
LT (2) | LT2663577T (fr) |
MA (1) | MA34907B1 (fr) |
ME (1) | ME02734B (fr) |
MX (1) | MX341489B (fr) |
MY (1) | MY162790A (fr) |
NL (1) | NL301159I2 (fr) |
PL (1) | PL2663577T3 (fr) |
PT (1) | PT2663577T (fr) |
RS (1) | RS56298B1 (fr) |
SG (2) | SG10201510762YA (fr) |
SI (1) | SI2663577T1 (fr) |
TN (1) | TN2013000292A1 (fr) |
TW (1) | TWI511978B (fr) |
UA (1) | UA110358C2 (fr) |
WO (1) | WO2012095662A1 (fr) |
ZA (1) | ZA201306080B (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0620729D0 (en) * | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
GB0807413D0 (en) * | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
WO2011144749A1 (fr) | 2010-05-20 | 2011-11-24 | Ablynx Nv | Matériaux biologiques associés à her3 |
RS56298B1 (sr) | 2011-01-14 | 2017-12-29 | Ucb Biopharma Sprl | Antitelo koje vezuje il-17a i il-17f |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
CN104583239B (zh) | 2012-05-10 | 2018-09-18 | 生物蛋白有限公司 | 多特异单克隆抗体 |
GB201310544D0 (en) | 2013-06-13 | 2013-07-31 | Ucb Pharma Sa | Obtaining an improved therapeutic ligand |
HUE052184T2 (hu) * | 2013-11-18 | 2021-12-28 | Shanghai hengrui pharmaceutical co ltd | IL-17A kötõanyag és felhasználásai |
KR20160124165A (ko) | 2014-02-21 | 2016-10-26 | 제넨테크, 인크. | 항-il-13/il-17 이중특이적 항체 및 그의 용도 |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
JP2018506275A (ja) | 2015-01-28 | 2018-03-08 | ジェネンテック, インコーポレイテッド | 多発性硬化症の遺伝子発現マーカー及び治療 |
MX2018005031A (es) | 2015-10-27 | 2018-06-13 | Ucb Biopharma Sprl | Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f). |
RU2680011C2 (ru) * | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
WO2018050028A1 (fr) | 2016-09-14 | 2018-03-22 | 北京韩美药品有限公司 | Anticorps se liant spécifiquement à il -17 a et fragment fonctionnel de celui-ci |
JP6876156B2 (ja) * | 2017-03-10 | 2021-05-26 | スージョウ カノヴァ バイオファーマシューティカル カンパニーリミテッドSuzhou Kanova Biopharmaceutical Co., Ltd. | Il−17a及びil−17fに反応するモノクローナル抗体、及びその使用 |
GB201719447D0 (en) * | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
US20210309735A1 (en) * | 2018-07-31 | 2021-10-07 | Weiqun SHEN | Anti-il-17a antibodies and use thereof |
CN110151999A (zh) * | 2019-05-22 | 2019-08-23 | 中国人民解放军第四军医大学 | 用于抑制恶性黑色素瘤进展的靶向药物 |
GB201919061D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
EP4393948A1 (fr) * | 2022-12-28 | 2024-07-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Anticorps vhh thérapeutiques neutralisant de manière croisée les homodimères il-17a et il-17f et l'hétérodimère il-17af |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
WO1991010737A1 (fr) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production d'anticorps utilisant des librairies de genes |
AU7766391A (en) | 1990-04-23 | 1991-11-11 | Corvas International N.V. | Thrombus-specific antibody derivatives |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0542810A1 (fr) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Procedes de production de proteines presentant une fonction souhaitee |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
NZ251957A (en) | 1992-04-27 | 1995-12-21 | Commw Of Australia | Radio communications modem: estimation of transmitted signal |
US6274711B1 (en) | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
WO1995015982A2 (fr) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Procede de generation d'anticorps specifiques |
WO1995020401A1 (fr) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Banques d'anticorps polyclonaux |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
CA2227220A1 (fr) | 1995-07-19 | 1997-02-06 | Genetics Institute, Inc. | Proteines humaines ctla-8 et utilisation de proteines apparentees aux proteines ctla-8 |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
AU2559799A (en) | 1998-01-22 | 1999-08-09 | Genentech Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same |
EP1053751A1 (fr) | 1999-05-17 | 2000-11-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions et méthodes pour le traitement des désordres de la prolifération cellulaire |
US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
ATE482719T1 (de) | 2002-02-21 | 2010-10-15 | Univ Duke | Behandlungsverfahren unter verwendung von anti- cd22-antikörpern |
US7993864B2 (en) | 2002-12-03 | 2011-08-09 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
US7989594B2 (en) | 2003-07-01 | 2011-08-02 | Celltech R & D Limited | Modified antibody fab fragments |
SI2784084T2 (sl) | 2003-07-08 | 2024-02-29 | Novartis Pharma Ag | Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom |
AU2004292393C1 (en) | 2003-11-21 | 2011-08-04 | Ucb Pharma S.A. | Method for the treatment of multiple sclerosis by inhibiting IL-17 activity |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
AU2005323025A1 (en) | 2004-12-31 | 2006-07-13 | Biogen Idec Ma Inc. | Polypeptides that bind BR3 and uses thereof |
JP2008532936A (ja) | 2005-02-14 | 2008-08-21 | ワイス | インターロイキン−17f抗体及び他のil−17fシグナル伝達拮抗物質並びにそれらの使用 |
BRPI0608210A2 (pt) | 2005-02-14 | 2010-11-09 | Wyeth Corp | métodos de diagnóstico de um distúrbio relacionado com il-17f em um indivìduo e de seleção de compostos capazes de inibirem a ligação de il-17f em il-17r, uso de um antagonista de il-17f, composição farmacêutica, e, adjuvante de vacina |
CN101316861A (zh) * | 2005-09-28 | 2008-12-03 | 津莫吉尼蒂克斯公司 | Il-17a和il-17f拮抗剂以及使用所述拮抗剂的方法 |
RS57255B1 (sr) | 2005-12-13 | 2018-08-31 | Lilly Co Eli | Anti-il-17 antitela |
EP2377887A1 (fr) | 2006-03-10 | 2011-10-19 | Zymogenetics Inc | Anticorps liant l'IL-17A et l'IL-17F et leurs procédés d'utilisation |
US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
BRPI0715917A2 (pt) | 2006-08-11 | 2014-11-25 | Schering Corp | Anticorpos para il-17a |
GB0620729D0 (en) * | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
TW200902064A (en) | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
CA2682889C (fr) | 2007-04-27 | 2016-04-05 | Zymogenetics, Inc. | Anticorps qui se lient a la fois a il-17a et il-17f et leurs procedes d'utilisation |
WO2008134659A2 (fr) | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antagonistes à il-17a, il-17f et il-23p19, et procédés d'utilisation de ceux-ci |
EP2535349A1 (fr) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Fusions d'anticorps à double spécificité |
GB0807413D0 (en) * | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
KR20170023209A (ko) | 2008-05-05 | 2017-03-02 | 노비뮨 에스 에이 | 항-il-17a/il-17f 교차-반응성 항체 및 그의 사용 방법 |
US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
US10407513B2 (en) | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
EP2453823B1 (fr) | 2009-07-14 | 2015-05-13 | WaveTec Vision Systems, Inc. | Système de mesure pour chirurgie ophtalmique |
EP2475682B1 (fr) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Anticorps multivalents |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
RS56298B1 (sr) | 2011-01-14 | 2017-12-29 | Ucb Biopharma Sprl | Antitelo koje vezuje il-17a i il-17f |
-
2012
- 2012-01-11 RS RS20170705A patent/RS56298B1/sr unknown
- 2012-01-11 ME MEP-2017-146A patent/ME02734B/fr unknown
- 2012-01-11 CN CN201280009581.4A patent/CN103384682B/zh active Active
- 2012-01-11 EP EP12700433.1A patent/EP2663577B1/fr active Active
- 2012-01-11 EA EA201300819A patent/EA037071B1/ru unknown
- 2012-01-11 LT LTEP12700433.1T patent/LT2663577T/lt unknown
- 2012-01-11 JP JP2013548889A patent/JP6028737B2/ja active Active
- 2012-01-11 PT PT127004331T patent/PT2663577T/pt unknown
- 2012-01-11 MX MX2013007956A patent/MX341489B/es active IP Right Grant
- 2012-01-11 SI SI201230994T patent/SI2663577T1/sl unknown
- 2012-01-11 BR BR112013017951-1A patent/BR112013017951B1/pt active IP Right Grant
- 2012-01-11 CA CA2823812A patent/CA2823812C/fr active Active
- 2012-01-11 AU AU2012206431A patent/AU2012206431B2/en active Active
- 2012-01-11 WO PCT/GB2012/050050 patent/WO2012095662A1/fr active Application Filing
- 2012-01-11 US US13/348,456 patent/US8580265B2/en active Active
- 2012-01-11 ES ES12700433.1T patent/ES2632583T3/es active Active
- 2012-01-11 PL PL12700433T patent/PL2663577T3/pl unknown
- 2012-01-11 MA MA36181A patent/MA34907B1/fr unknown
- 2012-01-11 EP EP17163570.9A patent/EP3219728A1/fr not_active Withdrawn
- 2012-01-11 MY MYPI2013701205A patent/MY162790A/en unknown
- 2012-01-11 KR KR1020137021367A patent/KR101950306B1/ko active IP Right Grant
- 2012-01-11 SG SG10201510762YA patent/SG10201510762YA/en unknown
- 2012-01-11 SG SG2013052741A patent/SG191906A1/en unknown
- 2012-01-11 DK DK12700433.1T patent/DK2663577T3/en active
- 2012-01-12 TW TW101101182A patent/TWI511978B/zh active
- 2012-01-12 AR ARP120100115A patent/AR084845A1/es active IP Right Grant
- 2012-11-01 UA UAA201309003A patent/UA110358C2/ru unknown
-
2013
- 2013-07-04 IL IL227347A patent/IL227347B/en active IP Right Grant
- 2013-07-10 TN TNP2013000292A patent/TN2013000292A1/fr unknown
- 2013-07-12 CL CL2013002044A patent/CL2013002044A1/es unknown
- 2013-08-12 CO CO13191259A patent/CO6781516A2/es not_active Application Discontinuation
- 2013-08-13 ZA ZA2013/06080A patent/ZA201306080B/en unknown
- 2013-11-08 US US14/074,880 patent/US9034600B2/en active Active
-
2015
- 2015-04-20 US US14/690,892 patent/US9988446B2/en active Active
-
2016
- 2016-10-03 JP JP2016195952A patent/JP2017046699A/ja active Pending
-
2017
- 2017-07-05 HR HRP20171034TT patent/HRP20171034T1/hr unknown
- 2017-07-12 CY CY20171100738T patent/CY1119055T1/el unknown
-
2018
- 2018-05-08 US US15/974,407 patent/US20180346561A1/en not_active Abandoned
-
2020
- 2020-12-15 US US17/122,752 patent/US11919950B2/en active Active
-
2022
- 2022-01-04 FR FR22C1000C patent/FR22C1000I2/fr active Active
- 2022-01-10 HU HUS2200001C patent/HUS2200001I1/hu unknown
- 2022-01-12 FI FIC20220002C patent/FIC20220002I1/fi unknown
- 2022-01-19 LT LTPA2022501C patent/LTPA2022501I1/lt unknown
- 2022-01-19 NL NL301159C patent/NL301159I2/nl unknown
- 2022-12-21 AR ARP220103527A patent/AR128047A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR22C1000I2 (fr) | Anticorps se liant a il-17a et il-17f | |
CY2019040I2 (el) | Aνti-il-23 αντισωματα | |
FR23C1023I2 (fr) | Anticorps anti-il-36r | |
DK2701739T3 (da) | Tolerogene syntetiske nanobærere til reducering af antistofresponser | |
DK2643349T3 (da) | Designede repeat-proteiner, der binder til serumalbumin | |
DK2797957T3 (da) | Bindingsmolekyler specifikke for her3 og anvendelser deraf | |
DK2633007T3 (da) | Produktion af regenererbar biobenzin | |
CL2014000126A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t. | |
DK2742135T4 (da) | Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf | |
BR112013014278A2 (pt) | proteínas de ligação a tnf-a | |
BRDI7103544S (pt) | Configuração aplicada a telefone celular | |
DK2721152T3 (da) | Dimere bindingsproteiner baseret på modificerede ubiquitiner | |
HK1211597A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 her3- her3 | |
DK2718326T3 (da) | Antistoffer mod g-csfr og anvendelser deraf | |
CO6900124A2 (es) | Mejora con relación a la construcción | |
DE112011101229A5 (de) | Geteiltes Schwungrad | |
BRDI7103543S (pt) | Configuração aplicada a telefone celular | |
DE112012003443A5 (de) | Zweimassenschwungrad | |
FI20105042A (fi) | Laite palamisen tehostamiseksi | |
BR112012017549A2 (pt) | método para fabricar um clipe resiliente | |
FR2960610B1 (fr) | Ecrou noye a sertir | |
DE112011101230A5 (de) | Geteiltes Schwungrad | |
ES1072573Y (es) | Elemento de mobiliario urbano multifuncional | |
ES1074761Y (es) | Cinemometro urbano | |
BRDI7105343S (pt) | Padrão ornamental aplicado em ilustração |